IL264589A - Combination therapy for the treatment of pancreatic cancer - Google Patents

Combination therapy for the treatment of pancreatic cancer

Info

Publication number
IL264589A
IL264589A IL264589A IL26458919A IL264589A IL 264589 A IL264589 A IL 264589A IL 264589 A IL264589 A IL 264589A IL 26458919 A IL26458919 A IL 26458919A IL 264589 A IL264589 A IL 264589A
Authority
IL
Israel
Prior art keywords
pancreatic cancer
combined treatment
treatment
combined
pancreatic
Prior art date
Application number
IL264589A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL264589A publication Critical patent/IL264589A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL264589A 2016-08-23 2019-01-31 Combination therapy for the treatment of pancreatic cancer IL264589A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378322P 2016-08-23 2016-08-23
PCT/US2017/047985 WO2018039211A1 (en) 2016-08-23 2017-08-22 Combination therapy for the treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
IL264589A true IL264589A (en) 2019-02-28

Family

ID=59762090

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264589A IL264589A (en) 2016-08-23 2019-01-31 Combination therapy for the treatment of pancreatic cancer

Country Status (11)

Country Link
US (2) US10933058B2 (enExample)
EP (1) EP3503922B1 (enExample)
JP (2) JP7579636B2 (enExample)
KR (1) KR20190039951A (enExample)
CN (1) CN109641058A (enExample)
AU (1) AU2017316618A1 (enExample)
BR (1) BR112019002945A2 (enExample)
CA (1) CA3034259A1 (enExample)
IL (1) IL264589A (enExample)
MX (1) MX2019002121A (enExample)
WO (1) WO2018039211A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190039951A (ko) * 2016-08-23 2019-04-16 제넨테크, 인크. 췌장암의 치료를 위한 병용요법
US20210220471A1 (en) * 2018-07-13 2021-07-22 Memorial Sloan Kettering Cancer Center Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer
CA3186465A1 (en) * 2019-10-22 2021-04-29 Chemistry Rx Methods for treating congenital epidermal hyperplasia
CN115243719B (zh) * 2020-03-06 2024-09-13 北京先通生物医药技术有限公司 CTB006与Ponatinib联合应用
CN115813930B (zh) * 2021-08-17 2026-05-26 赛诺哈勃药业（成都）有限公司 大环化合物与mek抑制剂联用在用于治疗疾病药物中的用途
CN116509852B (zh) * 2023-04-30 2026-07-31 兰州大学第二医院 含zinc218238819化合物的胰腺癌jak2和stat3双靶向抑制剂及应用
CN116585312B (zh) * 2023-04-30 2026-07-31 兰州大学第二医院 含苯氧基丙酸化合物的胰腺癌jak2和stat3双靶向抑制剂及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015175846A2 (en) * 2014-05-16 2015-11-19 University Of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016123054A2 (en) * 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
WO2016130917A1 (en) * 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
KR20190039951A (ko) * 2016-08-23 2019-04-16 제넨테크, 인크. 췌장암의 치료를 위한 병용요법

Also Published As

Publication number Publication date
CN109641058A (zh) 2019-04-16
JP7579636B2 (ja) 2024-11-08
KR20190039951A (ko) 2019-04-16
MX2019002121A (es) 2019-08-12
US12419879B2 (en) 2025-09-23
CA3034259A1 (en) 2018-03-01
US10933058B2 (en) 2021-03-02
US20190175576A1 (en) 2019-06-13
AU2017316618A1 (en) 2019-02-07
JP2024170398A (ja) 2024-12-10
BR112019002945A2 (pt) 2019-05-21
WO2018039211A1 (en) 2018-03-01
EP3503922A1 (en) 2019-07-03
US20210283120A1 (en) 2021-09-16
EP3503922B1 (en) 2022-10-26
JP2019526559A (ja) 2019-09-19

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL255261A0 (en) Methods for treating cancer
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
PL3283527T3 (pl) Leczenie skojarzone nowotworów
IL258684A (en) Combination therapy for treating malignancies
IL284875A (en) Lasofoxifene treatment of breast cancer
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
HUE059694T2 (hu) Készítmény rák kezelésére
LT3468965T (lt) 1-tetrahidropiranilkarbonil-2,3-dihidro-1h-indolo junginiai vėžio gydymui
PL3197456T3 (pl) Leczenie nowotworów
KR20180084772A (ko) 암 치료를 위한 조합 치료법
IL261047A (en) Taf1 inhibitors for the therapy of cancer
IL265697B1 (en) Treatment of prostate cancer
PL3622953T3 (pl) Leczenie skojarzone nowotworu
EP3413927A4 (en) CANCER THERAPY
IL256836B (en) Methods for treating cancer using apilimod
IL265751B (en) Immunogenic compounds for cancer therapy
DK3576740T3 (da) Cancerbehandling
HUE040167T2 (hu) Rákkezelés
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
IL281845A (en) Combination therapy for the treatment of cancer
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3407909T5 (da) Cancerbehandling